Antidepressant use tied to greater risk of pneumonia, COPD exacerbations: study
Adults with COPD who are prescribed antidepressants may need close monitoring for side effects, say UK researchers who found an increased risk of pneumonia and…
Article Type: Specialist Update
Which antiplatelet monotherapy is best for CAD secondary prevention?
Antiplatelet monotherapy with clopidogrel or ticagrelor may be safer and more effective for secondary prevention of cardiovascular events than aspirin alone, results from a large…
1 in 4 patients die within a year of first HF hospitalisation: study
Globally, one in four patients die within 12 months of their first heart failure-related hospitalisation, according to a study in JACC: Heart Failure. Dr Biykem…
MHT linked to dementia risk, even with short-term use: study
Editor’s note: The headline for this article has been updated. See response to comment below. Use of menopausal hormone therapy is linked to an elevated…
Moderate to severe psoriasis tied to lower fertility rates
Patients with moderate to severe psoriasis have lower fertility rates than women without psoriasis, according to a study in JAMA Dermatology. Dr Teng-Chou Chen (PhD),…
Surgery a viable first-line option for Crohn’s disease: doctors
Early ileocecal resection could be an effective first-line therapy for Crohn’s disease, according to Danish and US gastroenterologists, challenging the current paradigm of reserving surgery…
Faecal transplants ‘show promise’ for immune-mediated colitis
Patients with refractory immune checkpoint inhibitor-induced colitis may benefit from faecal microbiota transplants, according to a study in Science Translational Medicine. Doctors from the University…
Psychological monitoring should be routine post-ICD, cardiologists say
Patients who have received implantable cardioverter defibrillators regardless of indication should be closely monitored for mood disorders, results from a large meta-analysis suggest. Australian cardiologists…
Safe to stop immunotherapy at two years in advanced NSCLC: study
Patients who are progression-free on immunotherapy for advanced or metastatic lung cancer can safely discontinue therapy after two years, US oncologists report. Despite doctors’ “substantial…
Fixed-duration combo therapy shows promise for leukaemia
Fixed-duration ibrutinib plus venetoclax is beneficial for patients with chronic lymphocytic leukaemia, including those with high-risk features, according to a study in Clinical Cancer Research.…
